Table of Content

1 Live Attenuated Measles Vaccine Market Overview
1.1 Product Overview and Scope of Live Attenuated Measles Vaccine
1.2 Live Attenuated Measles Vaccine Segment by Type
1.2.1 Global Live Attenuated Measles Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Liquid
1.2.3 Powder
1.3 Live Attenuated Measles Vaccine Segment by Application
1.3.1 Global Live Attenuated Measles Vaccine Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Live Attenuated Measles Vaccine Market Size Estimates and Forecasts
1.4.1 Global Live Attenuated Measles Vaccine Revenue 2024-2034
1.4.2 Global Live Attenuated Measles Vaccine Sales 2024-2034
1.4.3 Global Live Attenuated Measles Vaccine Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Live Attenuated Measles Vaccine Market Competition by Manufacturers
2.1 Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2024-2024)
2.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Live Attenuated Measles Vaccine Average Price by Manufacturers (2024-2024)
2.4 Global Live Attenuated Measles Vaccine Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Live Attenuated Measles Vaccine, Product Type & Application
2.7 Live Attenuated Measles Vaccine Market Competitive Situation and Trends
2.7.1 Live Attenuated Measles Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Live Attenuated Measles Vaccine Players Market Share by Revenue
2.7.3 Global Live Attenuated Measles Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Live Attenuated Measles Vaccine Retrospective Market Scenario by Region
3.1 Global Live Attenuated Measles Vaccine Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Live Attenuated Measles Vaccine Global Live Attenuated Measles Vaccine Sales by Region: 2024-2034
3.2.1 Global Live Attenuated Measles Vaccine Sales by Region: 2024-2024
3.2.2 Global Live Attenuated Measles Vaccine Sales by Region: 2024-2034
3.3 Global Live Attenuated Measles Vaccine Global Live Attenuated Measles Vaccine Revenue by Region: 2024-2034
3.3.1 Global Live Attenuated Measles Vaccine Revenue by Region: 2024-2024
3.3.2 Global Live Attenuated Measles Vaccine Revenue by Region: 2024-2034
3.4 North America Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.4.1 North America Live Attenuated Measles Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Live Attenuated Measles Vaccine Sales by Country (2024-2034)
3.4.3 North America Live Attenuated Measles Vaccine Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.5.1 Europe Live Attenuated Measles Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Live Attenuated Measles Vaccine Sales by Country (2024-2034)
3.5.3 Europe Live Attenuated Measles Vaccine Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Live Attenuated Measles Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Live Attenuated Measles Vaccine Sales by Country (2024-2034)
3.6.3 Asia Pacific Live Attenuated Measles Vaccine Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.7.1 Latin America Live Attenuated Measles Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Live Attenuated Measles Vaccine Sales by Country (2024-2034)
3.7.3 Latin America Live Attenuated Measles Vaccine Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2024-2034)
3.8.3 Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Live Attenuated Measles Vaccine Sales by Type (2024-2034)
4.1.1 Global Live Attenuated Measles Vaccine Sales by Type (2024-2024)
4.1.2 Global Live Attenuated Measles Vaccine Sales by Type (2024-2034)
4.1.3 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2024-2034)
4.2 Global Live Attenuated Measles Vaccine Revenue by Type (2024-2034)
4.2.1 Global Live Attenuated Measles Vaccine Revenue by Type (2024-2024)
4.2.2 Global Live Attenuated Measles Vaccine Revenue by Type (2024-2034)
4.2.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2024-2034)
4.3 Global Live Attenuated Measles Vaccine Price by Type (2024-2034)
5 Segment by Application
5.1 Global Live Attenuated Measles Vaccine Sales by Application (2024-2034)
5.1.1 Global Live Attenuated Measles Vaccine Sales by Application (2024-2024)
5.1.2 Global Live Attenuated Measles Vaccine Sales by Application (2024-2034)
5.1.3 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2024-2034)
5.2 Global Live Attenuated Measles Vaccine Revenue by Application (2024-2034)
5.2.1 Global Live Attenuated Measles Vaccine Revenue by Application (2024-2024)
5.2.2 Global Live Attenuated Measles Vaccine Revenue by Application (2024-2034)
5.2.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2024-2034)
5.3 Global Live Attenuated Measles Vaccine Price by Application (2024-2034)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Sanofi-Pasteur
6.2.1 Sanofi-Pasteur Corporation Information
6.2.2 Sanofi-Pasteur Description and Business Overview
6.2.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.2.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
6.2.5 Sanofi-Pasteur Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Merck Live Attenuated Measles Vaccine Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Serum Institute of India
6.5.1 Serum Institute of India Corporation Information
6.5.2 Serum Institute of India Description and Business Overview
6.5.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
6.5.5 Serum Institute of India Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Emergent Biosolutions
6.6.1 Emergent Biosolutions Corporation Information
6.6.2 Emergent Biosolutions Description and Business Overview
6.6.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
6.7.5 Emergent Biosolutions Recent Developments/Updates
6.8 Bavarian Nordic
6.8.1 Bavarian Nordic Corporation Information
6.8.2 Bavarian Nordic Description and Business Overview
6.8.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
6.8.5 Bavarian Nordic Recent Developments/Updates
6.9 Medimmune
6.9.1 Medimmune Corporation Information
6.9.2 Medimmune Description and Business Overview
6.9.3 Medimmune Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
6.9.5 Medimmune Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Corporation Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 CSL Limited
6.11.1 CSL Limited Corporation Information
6.11.2 CSL Limited Live Attenuated Measles Vaccine Description and Business Overview
6.11.3 CSL Limited Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.11.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
6.11.5 CSL Limited Recent Developments/Updates
6.12 Changchun Qijian Biological Products Co., Ltd
6.12.1 Changchun Qijian Biological Products Co., Ltd Corporation Information
6.12.2 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.12.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.12.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.12.5 Changchun Qijian Biological Products Co., Ltd Recent Developments/Updates
6.13 Beijing Institute of Biological Products Co., Ltd
6.13.1 Beijing Institute of Biological Products Co., Ltd Corporation Information
6.13.2 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.13.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.13.5 Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
6.14 Wuhan Institute of Biological Products Co., Ltd
6.14.1 Wuhan Institute of Biological Products Co., Ltd Corporation Information
6.14.2 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.14.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.14.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.14.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
6.15 Shanghai Institute of Biological Products Co., Ltd
6.15.1 Shanghai Institute of Biological Products Co., Ltd Corporation Information
6.15.2 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.15.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.15.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.15.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
6.16 Lanzhou Institute of Biological Products Co., Ltd
6.16.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
6.16.2 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.16.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.16.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.16.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Live Attenuated Measles Vaccine Industry Chain Analysis
7.2 Live Attenuated Measles Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Live Attenuated Measles Vaccine Production Mode & Process
7.4 Live Attenuated Measles Vaccine Sales and Marketing
7.4.1 Live Attenuated Measles Vaccine Sales Channels
7.4.2 Live Attenuated Measles Vaccine Distributors
7.5 Live Attenuated Measles Vaccine Customers
8 Live Attenuated Measles Vaccine Market Dynamics
8.1 Live Attenuated Measles Vaccine Industry Trends
8.2 Live Attenuated Measles Vaccine Market Drivers
8.3 Live Attenuated Measles Vaccine Market Challenges
8.4 Live Attenuated Measles Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Live Attenuated Measles Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Live Attenuated Measles Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Live Attenuated Measles Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Live Attenuated Measles Vaccine Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Live Attenuated Measles Vaccine Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Live Attenuated Measles Vaccine Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Live Attenuated Measles Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Live Attenuated Measles Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Live Attenuated Measles Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Live Attenuated Measles Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Measles Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Live Attenuated Measles Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Live Attenuated Measles Vaccine Sales by Region (2024-2024) & (K Units)
Table 18. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2024-2024)
Table 19. Global Live Attenuated Measles Vaccine Sales by Region (2024-2034) & (K Units)
Table 20. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2024-2034)
Table 21. Global Live Attenuated Measles Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2024-2024)
Table 23. Global Live Attenuated Measles Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2024-2034)
Table 25. North America Live Attenuated Measles Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Live Attenuated Measles Vaccine Sales by Country (2024-2024) & (K Units)
Table 27. North America Live Attenuated Measles Vaccine Sales by Country (2024-2034) & (K Units)
Table 28. North America Live Attenuated Measles Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Live Attenuated Measles Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Live Attenuated Measles Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Live Attenuated Measles Vaccine Sales by Country (2024-2024) & (K Units)
Table 32. Europe Live Attenuated Measles Vaccine Sales by Country (2024-2034) & (K Units)
Table 33. Europe Live Attenuated Measles Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Live Attenuated Measles Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Live Attenuated Measles Vaccine Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Live Attenuated Measles Vaccine Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Live Attenuated Measles Vaccine Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Live Attenuated Measles Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Live Attenuated Measles Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Live Attenuated Measles Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Live Attenuated Measles Vaccine Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Live Attenuated Measles Vaccine Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Live Attenuated Measles Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Live Attenuated Measles Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Live Attenuated Measles Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Live Attenuated Measles Vaccine Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Live Attenuated Measles Vaccine Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Live Attenuated Measles Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Live Attenuated Measles Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Live Attenuated Measles Vaccine Sales (K Units) by Type (2024-2024)
Table 51. Global Live Attenuated Measles Vaccine Sales (K Units) by Type (2024-2034)
Table 52. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2024-2024)
Table 53. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2024-2034)
Table 54. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2024-2024)
Table 57. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2024-2034)
Table 58. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Type (2024-2024)
Table 59. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Type (2024-2034)
Table 60. Global Live Attenuated Measles Vaccine Sales (K Units) by Application (2024-2024)
Table 61. Global Live Attenuated Measles Vaccine Sales (K Units) by Application (2024-2034)
Table 62. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2024-2024)
Table 63. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2024-2034)
Table 64. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2024-2024)
Table 67. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2024-2034)
Table 68. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Application (2024-2024)
Table 69. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Application (2024-2034)
Table 70. GSK Corporation Information
Table 71. GSK Description and Business Overview
Table 72. GSK Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. GSK Live Attenuated Measles Vaccine Product
Table 74. GSK Recent Developments/Updates
Table 75. Sanofi-Pasteur Corporation Information
Table 76. Sanofi-Pasteur Description and Business Overview
Table 77. Sanofi-Pasteur Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. Sanofi-Pasteur Live Attenuated Measles Vaccine Product
Table 79. Sanofi-Pasteur Recent Developments/Updates
Table 80. Merck Corporation Information
Table 81. Merck Description and Business Overview
Table 82. Merck Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. Merck Live Attenuated Measles Vaccine Product
Table 84. Merck Recent Developments/Updates
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Pfizer Live Attenuated Measles Vaccine Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Serum Institute of India Corporation Information
Table 91. Serum Institute of India Description and Business Overview
Table 92. Serum Institute of India Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Serum Institute of India Live Attenuated Measles Vaccine Product
Table 94. Serum Institute of India Recent Developments/Updates
Table 95. Novartis Corporation Information
Table 96. Novartis Description and Business Overview
Table 97. Novartis Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Novartis Live Attenuated Measles Vaccine Product
Table 99. Novartis Recent Developments/Updates
Table 100. Emergent Biosolutions Corporation Information
Table 101. Emergent Biosolutions Description and Business Overview
Table 102. Emergent Biosolutions Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Emergent Biosolutions Live Attenuated Measles Vaccine Product
Table 104. Emergent Biosolutions Recent Developments/Updates
Table 105. Bavarian Nordic Corporation Information
Table 106. Bavarian Nordic Description and Business Overview
Table 107. Bavarian Nordic Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. Bavarian Nordic Live Attenuated Measles Vaccine Product
Table 109. Bavarian Nordic Recent Developments/Updates
Table 110. Medimmune Corporation Information
Table 111. Medimmune Description and Business Overview
Table 112. Medimmune Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Medimmune Live Attenuated Measles Vaccine Product
Table 114. Medimmune Recent Developments/Updates
Table 115. Johnson & Johnson Corporation Information
Table 116. Johnson & Johnson Description and Business Overview
Table 117. Johnson & Johnson Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Johnson & Johnson Live Attenuated Measles Vaccine Product
Table 119. Johnson & Johnson Recent Developments/Updates
Table 120. CSL Limited Corporation Information
Table 121. CSL Limited Description and Business Overview
Table 122. CSL Limited Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. CSL Limited Live Attenuated Measles Vaccine Product
Table 124. CSL Limited Recent Developments/Updates
Table 125. Changchun Qijian Biological Products Co., Ltd Corporation Information
Table 126. Changchun Qijian Biological Products Co., Ltd Description and Business Overview
Table 127. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 128. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 129. Changchun Qijian Biological Products Co., Ltd Recent Developments/Updates
Table 130. Beijing Institute of Biological Products Co., Ltd Corporation Information
Table 131. Beijing Institute of Biological Products Co., Ltd Description and Business Overview
Table 132. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 133. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 134. Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 135. Wuhan Institute of Biological Products Co., Ltd Corporation Information
Table 136. Wuhan Institute of Biological Products Co., Ltd Description and Business Overview
Table 137. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 138. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 139. Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 140. Shanghai Institute of Biological Products Co., Ltd Corporation Information
Table 141. Shanghai Institute of Biological Products Co., Ltd Description and Business Overview
Table 142. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 143. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 144. Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 145. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
Table 146. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
Table 147. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 148. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 149. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Live Attenuated Measles Vaccine Distributors List
Table 153. Live Attenuated Measles Vaccine Customers List
Table 154. Live Attenuated Measles Vaccine Market Trends
Table 155. Live Attenuated Measles Vaccine Market Drivers
Table 156. Live Attenuated Measles Vaccine Market Challenges
Table 157. Live Attenuated Measles Vaccine Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Live Attenuated Measles Vaccine
Figure 2. Global Live Attenuated Measles Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Live Attenuated Measles Vaccine Market Share by Type in 2022 & 2034
Figure 4. Liquid Product Picture
Figure 5. Powder Product Picture
Figure 6. Global Live Attenuated Measles Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Live Attenuated Measles Vaccine Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Live Attenuated Measles Vaccine Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 11. Global Live Attenuated Measles Vaccine Market Size (2024-2034) & (US$ Million)
Figure 12. Global Live Attenuated Measles Vaccine Sales (2024-2034) & (K Units)
Figure 13. Global Live Attenuated Measles Vaccine Average Price (US$/Unit) & (2024-2034)
Figure 14. Live Attenuated Measles Vaccine Report Years Considered
Figure 15. Live Attenuated Measles Vaccine Sales Share by Manufacturers in 2022
Figure 16. Global Live Attenuated Measles Vaccine Revenue Share by Manufacturers in 2022
Figure 17. The Global 5 and 10 Largest Live Attenuated Measles Vaccine Players: Market Share by Revenue in 2022
Figure 18. Live Attenuated Measles Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 19. Global Live Attenuated Measles Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 20. North America Live Attenuated Measles Vaccine Sales Market Share by Country (2024-2034)
Figure 21. North America Live Attenuated Measles Vaccine Revenue Market Share by Country (2024-2034)
Figure 22. United States Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 23. Canada Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 24. Europe Live Attenuated Measles Vaccine Sales Market Share by Country (2024-2034)
Figure 25. Europe Live Attenuated Measles Vaccine Revenue Market Share by Country (2024-2034)
Figure 26. Germany Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 27. France Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 28. U.K. Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. Italy Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. Russia Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. Asia Pacific Live Attenuated Measles Vaccine Sales Market Share by Region (2024-2034)
Figure 32. Asia Pacific Live Attenuated Measles Vaccine Revenue Market Share by Region (2024-2034)
Figure 33. China Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Japan Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 35. South Korea Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. India Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. Australia Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. China Taiwan Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. Southeast Asia Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Latin America Live Attenuated Measles Vaccine Sales Market Share by Country (2024-2034)
Figure 41. Latin America Live Attenuated Measles Vaccine Revenue Market Share by Country (2024-2034)
Figure 42. Mexico Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. Brazil Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 44. Argentina Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Middle East & Africa Live Attenuated Measles Vaccine Sales Market Share by Country (2024-2034)
Figure 46. Middle East & Africa Live Attenuated Measles Vaccine Revenue Market Share by Country (2024-2034)
Figure 47. Turkey Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Saudi Arabia Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 49. UAE Live Attenuated Measles Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. Global Sales Market Share of Live Attenuated Measles Vaccine by Type (2024-2034)
Figure 51. Global Revenue Market Share of Live Attenuated Measles Vaccine by Type (2024-2034)
Figure 52. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Type (2024-2034)
Figure 53. Global Sales Market Share of Live Attenuated Measles Vaccine by Application (2024-2034)
Figure 54. Global Revenue Market Share of Live Attenuated Measles Vaccine by Application (2024-2034)
Figure 55. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Application (2024-2034)
Figure 56. Live Attenuated Measles Vaccine Value Chain
Figure 57. Live Attenuated Measles Vaccine Production Process
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed